Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Trial details
- Registry ID
- NCT00589875
- Phase
- Phase 2
The FDA approved Valacyclovir (Valtrex) on 23 Jun 1995.
Drug identity checked against registry records
Also recorded as Valtrex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875 | CADL | Phase 2 | Completed | 2015-12Actual |
| Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094 | CADL | Phase 3 | Recruiting | 2031-10-22Estimated |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153 | CADL | Phase 2 | Active not recruiting | 2024-12-31Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1995-06-23Day | Valacyclovir | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020487", "applicant_as_listed_by_fda": "GLAXOSMITHKLINE", "brand_names": ["VALTREX"], "active_ingredients": ["VALACYCLOVIR HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19950623", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |